This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacobson, M A Articles by Mills, J Search for Related Content PubMed PubMed Citation Articles by Jacobson, M A Articles by Mills, J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 May; 33(5): 736-741

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

Department of Medicine, University of California, San Francisco.

ABSTRACT

Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days. At the end of induction, 9 of 10 patients had stabilized (no new retinal lesions and stable old lesions [7 patients]) or improved (decreased retinal opacification [2 patients]). All eight patients with CMV in urine or blood upon entry into the study had negative urine and blood cultures at the end of induction. After induction therapy, seven patients continued maintenance foscarnet therapy, 60 mg/kg as a single daily infusion, 5 days/week. In six patients, retinal lesions increased in size after 2 to 32 weeks of maintenance therapy. One was invaluable because a retinal detachment developed. Only 9 of 42 blood and urine cultures obtained during maintenance foscarnet therapy yielded CMV, compared with 7 of 14 obtained prior to the initiation of foscarnet induction therapy (P = 0.04). Foscarnet toxicity was mild and infrequent: elevation in serum creatinine by 0.5 to 1.3 mg/dl over the base line (two patients), muscle twitching (three patients), hemoglobin decrease by 1 mg/dl (two patients), nausea (two patients), absolute neutrophil count decrease by 50% (one patient), rise in serum phosphorus to greater than 5.5 mg/dl (four patients), and proteinuria (two patients). Intermittently administered intravenous foscarnet appears to be an effective, relatively nontoxic therapy for CMV retinitis. Additional studies to determine the optimal dosage for maintenance therapy are needed, as are comparative trials with ganciclovir.

This article has been cited by other articles:

• Bochot, A., Fattal, E., Boutet, V., Deverre, J. R., Jeanny, J. C., Chacun, H., Couvreur, P. (2002). Intravitreal Delivery of Oligonucleotides by Sterically Stabilized Liposomes. IOVS 43: 253-259 [Abstract] [Full Text]  
• Huycke, M. M., Naguib, M. T., Stroemmel, M. M., Blick, K., Monti, K., Martin-Munley, S., Kaufman, C. (2000). A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection. Antimicrob. Agents Chemother. 44: 2143-2148 [Abstract] [Full Text]  
• Musch, D. C., Martin, D. F., Gordon, J. F., Davis, M. D., Kuppermann, B. D., The Ganciclovir Implant Study Group, (1997). Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir Implant. NEJM 337: 83-90 [Abstract] [Full Text]  
• Jacobson, M. A. (1997). Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome. NEJM 337: 105-114 [Full Text]  
• Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M. J., The Roche Cooperative Oral Ganciclovir Study Group, (1996). Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. NEJM 334: 1491-1497 [Abstract] [Full Text]  
• Drew, W. L., Ives, D., Lalezari, J. P., Crumpacker, C., Follansbee, S. E., Spector, S. A., Benson, C. A., Friedberg, D. N., Hubbard, L., Stempien, M. J., Shadman, A., Buhles, W., The Syntex Cooperative Oral Ganciclovir Study Grou, (1995). Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDS. NEJM 333: 615-620 [Abstract] [Full Text]